Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02805660
Title Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Southern Cancer Center, PC Mobile Alabama 36608 United States Details
David Geffen School of Medicine at UCLA Los Angeles California 90095 United States Details
Woodlands Medical Specialists - Pensacola Pensacola Florida 32503 United States Details
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago Illinois 60611 United States Details
NorthShore University Health System Evanston Illinois 60201 United States Details
Unniversity of Minnesota Masonic Cancer Center Minneapolis Minnesota 55414 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Montefiore Medical Center Bronx New York 10461 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Research Centers Dallas Texas 75230 United States Details
Texas Oncology - Denton South Denton Texas 76210 United States Details
Texas Oncology-Plano West Plano Texas 75093 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
Shenandoah Oncology - Winchester Winchester Virginia 22601 United States Details
Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field